What is lung cancer?
Lung cancer, also known as lung carcinoma, is characterised by uncontrolled cell growth in tissues of the lung. The two main types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC)1. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers2.
With an incidence of 1.8 million, lung cancer was the most common cancer worldwide in 2012, contributing 13% of the total number of new cases diagnosed3.
Treatment and long-term outcomes depend on the type of lung cancer, the stage (degree of spread), and the person’s overall health. Common lung cancer treatments include surgery, chemotherapy, and radiotherapy. NSCLC is sometimes treated with surgery, whereas SCLC usually responds better to chemotherapy and radiotherapy1.
1. Lung Cancer – Patient Version,
National Cancer Institute, cited on 13/03/2018
2. Non-Small Cell Lung Cancer,
Medscape, February 2018, cited on 13/03/2018
3. Cancer facts & figures – Worldwide data,
World Cancer Research Fund International, 2014
- Alecensa (alectinib)
by Roche Registration GmbH for Lung Cancer€7,700.00
- Alunbrig (brigatinib)
by ARIAD Pharmaceuticals, Inc. for Lung Cancer€3,657.00
- Imfinzi (durvalumab)
by AstraZeneca Pharmaceuticals LP for Urothelial Carcinoma, Lung Cancer€1,495.00
- Keytruda (pembrolizumab)
by Merck Sharp & Dohme Limited for Urothelial Carcinoma, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Skin Cancer€1,572.15
- Opdivo (nivolumab)
by Bristol-Myers Squibb Pharma EEIG for Urothelial Carcinoma, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Lymphoma, Skin Cancer€540.50
- Portrazza (necitumumab)
by Eli Lilly Nederland B.V. for Lung Cancer€672.75
- Tagrisso (osimertinib)
by AstraZeneca AB for Lung Cancer€8,619.25
- Tecentriq (atezolizumab)
by Roche Registration Limited for Urothelial Carcinoma, Lung Cancer€6,463.00
- Zykadia (ceritinib)
by Novartis Europharm Limited for Lung Cancer€6,037.50